Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Ocugen (NASDAQ: OCGN) will host a live webcast and conference call at 8:00 a.m. EDT on Tuesday, March 24, 2026 to discuss full Phase 2 ArMaDa clinical trial data for OCU410, a modifier gene therapy for geographic atrophy (late-stage dry AMD).

Rhea-AI Summary

Ocugen (NASDAQ: OCGN) will host a live webcast and conference call at 8:00 a.m. EDT on Tuesday, March 24, 2026 to discuss full Phase 2 ArMaDa clinical trial data for OCU410, a modifier gene therapy for geographic atrophy (late-stage dry AMD).

Key opinion leaders and Ocugen executives will present; a replay and archived webcast will be available on the company investor site. Dial-in and webcast details provided for attendees.

Argus Mar 23 session

+2.94% close to close Open Argus

Details

News Market Reaction – OCGN

On Mar 23, the day this news came out, OCGN closed 2.94% above the previous close.

Data tracked by StockTitan Argus for the Mar 23 session.

Key Figures

Webcast time: 8 a.m. EDT Webcast date: March 24, 2026 US dial-in: (800) 715-9871 +2 more

Webcast time

8 a.m. EDT

Scheduled OCU410 Phase 2 data webcast on March 24, 2026

Webcast date

March 24, 2026

Conference call and webcast to discuss full Phase 2 ArMaDa dataset

US dial-in

(800) 715-9871

U.S. access number for Ocugen OCU410 Phase 2 data call

International dial-in

(646) 307-1963

International access number for OCU410 webcast

Conference ID

4629682

Conference identifier for March 24, 2026 OCU410 webcast

Previous Clinical trial Reports

5 past events · Latest: Mar 02

Same Type 5 events

1. Mar 02

   Phase 3 enrollment

   24h Move

   +6.6%

   Completion of 140‑patient Phase 3 liMeliGhT enrollment for OCU400.

2. Jan 15

   Phase 2 data

   24h Move

   -13.8%

   Positive preliminary 12‑month Phase 2 OCU410 data in geographic atrophy.

3. Jan 13

   Data webcast

   24h Move

   +7.3%

   Announcement of webcast to review OCU410 Phase 2 ArMaDa clinical data.

4. Jan 12

   Phase 1 results

   24h Move

   +18.7%

   Publication of Phase 1 GARDian1 OCU410ST data with efficacy and safety.

5. Jul 18

   Pivotal trial start

   24h Move

   +2.0%

   First patient dosed in Phase 2/3 GARDian3 pivotal trial for OCU410ST.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2, clinical trial, modifier gene therapy, geographic atrophy, +1 more

5 terms

phase 2 medical

"full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

clinical trial medical

"Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

modifier gene therapy medical

"OCU410—Modifier Gene Therapy for Geographic Atrophy"

Modifier gene therapy is a treatment that changes the activity of genes that influence how severe or how a disease progresses, rather than directly fixing the original faulty gene. Think of it as turning a volume knob on disease symptoms: it can make conditions milder or slow progression, which matters to investors because it can expand the number of patients who benefit, affect how quickly and cheaply a product can reach the market, and change commercial and regulatory risk and reward.

geographic atrophy medical

"evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related"

Geographic atrophy is a progressive eye condition in which patches of light-sensing cells in the retina die, causing growing blind spots and ultimately significant central vision loss. For investors, it matters because the condition defines the market size and urgency for drugs, devices, and diagnostics — like a spreading hole in a photograph that companies aim to stop or repair — so clinical results, approvals, and reimbursement determine potential revenue and risk.

age-related macular degeneration medical

"late-stage dry age-related macular degeneration (dAMD) at 8 a.m."

Age-related macular degeneration is an eye condition in older adults where the central part of the retina (the macula) progressively loses function, blurring or erasing the sharp, central vision used for reading, driving, and recognizing faces. Investors care because it creates sustained demand for drugs, medical devices, diagnostics, and care services—think of the macula as the camera’s center; if it fails, the market for treatments and related healthcare products can be large and long-lasting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026.

KOLs leading the webcast include:

• Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocugen Scientific Advisory Board
  
  
• Jay Chhablani, MD, Professor, University of Pittsburgh and UPMC Vision Institute, and President of NetraMind
  

Victor H. Gonzalez, MD, Retinal Surgeon, Valley Retina Institute, McAllen, Texas, Faculty at University of Texas Rio Grande Valley; and Syed M. Shah, MD, Vice Chair for Research and Digital Medicine, Director of Retina Service, Department of Ophthalmology at Emplfiy Health, La Crosse, WI, Ibn al-Haytham Professor, Department of Ophthalmology, Aga Khan University will join to answer questions.

Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 4629682
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available following the event on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Ocugen (OCGN) presenting Phase 2 ArMaDa data for OCU410?

Ocugen will present on March 24, 2026 at 8:00 a.m. EDT. According to the company, the webcast will cover the full Phase 2 ArMaDa data set for OCU410 in geographic atrophy.

How can investors join the Ocugen (OCGN) March 24, 2026 webcast for OCU410 results?

Investors can join via live webcast on the Ocugen investor site or by phone using provided dial-in numbers. According to the company, a conference ID (4629682) is available for call access.

Who are the key opinion leaders speaking on Ocugen's OCU410 Phase 2 webcast?

Speakers include Lejla Vajzovic MD, Jay Chhablani MD, Victor H. Gonzalez MD, and Syed M. Shah MD. According to the company, these KOLs will join Ocugen leadership to discuss and answer questions.

Will Ocugen (OCGN) provide a replay of the March 24, 2026 OCU410 webcast?

Yes. A replay and archived webcast will be available after the event on the Ocugen investor site. According to the company, the recording will be posted following the live presentation and Q&A session.

What will the Ocugen (OCGN) webcast on March 24, 2026 focus on regarding OCU410?

The webcast will focus on the full Phase 2 ArMaDa clinical trial data for OCU410 in geographic atrophy (late-stage dry AMD). According to the company, presentations will include data review and a KOL-led Q&A with Ocugen executives.